CureVac's COVID-19 Vax Shows Comparable Antibody Levels To Pfizer/BioNTech's Shot In Animal Study

CureVac BV CVAC has announced the online publication of the extended preclinical study of the second-generation vaccine candidate, CV2CoV, jointly developed with GlaxoSmithKline Plc GSK, in the journal Nature.
Related Link: CureVac-GSK's Second-Gen COVID-19 Vaccine Candidate Shows Encouraging Action Against Variants In Animal Study.
The newly published data features a direct comparison of CV2CoV with the licensed mRNA vaccine, Pfizer Inc PFE / BioNTech SE's BNTX COVID-19 shot, Comirnaty.
Neutralizing antibody levels measured following complete vaccination of animals with either 12µg of CV2CoV or a 30µg standard dose of Comirnaty were shown to be highly comparable.
The data confirm how targeted optimizations of a non-chemically modified mRNA can significantly improve immune responses in a preclinical model.
Also Read: CureVac Shares Fall After Cutting COVID-19 Vaccine Production Plans.
Price Action: CVAC shares are up 4.43% at $41.43 during the market session on the last check Thursday.